Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Nephrology
Volume 2018, Article ID 2781789, 4 pages
https://doi.org/10.1155/2018/2781789
Case Report

Clinical Relapses of Atypical HUS on Eculizumab: Clinical Gap for Monitoring and Individualised Therapy

1Division of Nephrology, The Hospital for Sick Children, Toronto, ON, Canada
2Department of Paediatric Nephrology & Transplantation, The Children’s University Hospital, Temple Street, Dublin 1, Ireland
3Department of Paediatrics, University of Toronto, Toronto, ON, Canada
4Department of Neurology, The Children’s University Hospital, Temple Street, Dublin 1, Ireland
5Institute of Genetic Medicine, Newcastle University, International Centre for Life, Central Parkway, Newcastle upon Tyne, UK
6Department of Paediatric Nephrology, Our Lady’s Children’s Hospital, Crumlin, Dublin 12., Ireland

Correspondence should be addressed to Chia Wei Teoh; ac.sdikkcis@hoet.iewaihc

Received 25 November 2017; Accepted 4 January 2018; Published 6 February 2018

Academic Editor: Salih Kavukcu

Copyright © 2018 Chia Wei Teoh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Noris and G. Remuzzi, “Atypical hemolytic-uremic syndrome,” The New England Journal of Medicine, vol. 361, no. 17, pp. 1676–1687, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. C. Loirat and V. Frémeaux-Bacchi, “Atypical hemolytic uremic syndrome,” Orphanet Journal of Rare Diseases, vol. 6, article 60, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. C. M. Legendre, C. Licht, P. Muus et al., “Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome,” The New England Journal of Medicine, vol. 368, no. 23, pp. 2169–2181, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Licht, L. A. Greenbaum, P. Muus et al., “Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies,” Kidney International, vol. 87, no. 5, pp. 1061–1073, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. L. A. Greenbaum, M. Fila, G. Ardissino et al., “Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome,” Kidney International, vol. 89, no. 3, pp. 701–711, 2016. View at Publisher · View at Google Scholar · View at Scopus
  6. F. Fakhouri, M. Hourmant, J. M. Campistol et al., “Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial,” American Journal of Kidney Diseases, vol. 68, no. 1, pp. 84–93, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. R. D. Gilbert, D. J. Fowler, E. Angus, S. A. Hardy, L. Stanley, and T. H. Goodship, “Eculizumab therapy for atypical haemolytic uraemic syndrome due to a gain-of-function mutation of complement factor B,” Pediatric Nephrology, vol. 28, no. 8, pp. 1315–1318, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Atrouni, A. Darazé, J. Tamraz, A. Cassia, C. Caillaud, and A. Mégarbané, “Leukodystrophy associated with oligodontia in a a large inbred family: fortuitous association or new entity?” American Journal of Medical Genetics, vol. 118, no. 1, pp. 76–81, 2003. View at Google Scholar · View at Scopus
  9. N. I. Wolf, A. Vanderver, R. M. van Spaendonk et al., “Clinical spectrum of 4H leukodystrophy caused by POLR3A and POLR3B mutations,” Neurology, vol. 83, no. 21, pp. 1898–1905, 2014. View at Publisher · View at Google Scholar
  10. M. Tétreault, K. Choquet, S. Orcesi et al., “Recessive mutations in POLR3B, encoding the second largest subunit of Pol III, cause a rare hypomyelinating leukodystrophy,” American Journal of Human Genetics, vol. 89, no. 5, pp. 652–655, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. N. Besbas, B. Gulhan, D. Karpman et al., “Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab,” Pediatric Nephrology, vol. 28, no. 1, pp. 155–158, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. F. S. Cayci, N. Cakar, V. S. Hancer, N. Uncu, B. Acar, and G. Gur, “Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation,” Pediatric Nephrology, vol. 27, no. 12, pp. 2327–2331, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. S. I. Al-Akash, P. S. Almond, V. H. Savell Jr., S. I. Gharaybeh, and C. Hogue, “Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation,” Pediatric Nephrology, vol. 26, no. 4, pp. 613–619, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Goicoechea de Jorge, C. L. Harris, J. Esparza-Gordillo et al., “Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 104, no. 1, pp. 240–245, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Vilalta, E. Lara, A. Madrid et al., “Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome,” Pediatric Nephrology, vol. 27, no. 12, pp. 2323–2326, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. E. B. Volokhina, D. Westra, T. J. A. M. van der Velden, N. C. A. J. van de Kar, T. E. Mollnes, and L. P. van den Heuvel, “Complement activation patterns in atypical haemolytic uraemic syndrome during acute phase and in remission,” Clinical & Experimental Immunology, vol. 181, no. 2, pp. 306–313, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Noris, M. Galbusera, S. Gastoldi et al., “Dynamics of complement activation in aHUS and how to monitor eculizumab therapy,” Blood, vol. 124, no. 11, pp. 1715–1726, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. C. W. Teoh, M. Riedl, and C. Licht, “The alternative pathway of complement and the thrombotic microangiopathies,” Transfusion and Apheresis Science, vol. 54, no. 2, pp. 220–231, 2016. View at Publisher · View at Google Scholar · View at Scopus